Antonius van Dijk - 16 Jan 2024 Form 4 Insider Report for MiNK Therapeutics, Inc. (INKT)

Role
Chief Scientific Officer
Signature
By: /s/ Christine Klaskin, Attorney-in-Fact for Marc Antonius van Dijk
Issuer symbol
INKT
Transactions as of
16 Jan 2024
Transactions value $
$0
Form type
4
Filing time
18 Jan 2024, 20:00:08 UTC
Previous filing
12 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INKT Stock Option Award $0 +15,000 $0 15,000 16 Jan 2024 Common Stock 15,000 $0.87 Direct F1
transaction INKT Stock Option Award $0 +171,078 $0 171,078 16 Jan 2024 Common Stock 171,078 $0.87 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 An option to purchase Common Stock was granted to Dr. van Dijk on January 16, 2024 and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. The option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the grant date, with the remainder vesting in equal quarterly installments thereafter.
F2 An option to purchase Common Stock was granted to Dr. van Dijk on January 16, 2024 for his performance in 2023, and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. Half of the options will vest on June 27, 2024 and half of the options will vest on September 27, 2024.